We are supporting people working on the front lines of infectious disease
BOA’s technology is easily scalable to new pathogens. The same technology used to track and identify bacteria and fungi can be applied to coronavirus.
Our engineered protein was able to capture and identify pseudo SARS-CoV-2 virus and BOA is now expanding testing to actual SARS-CoV-2 clinical samples as well as other related coronaviruses.
The technology will be entering fast-track human clinical trials this year.
In summary, BOA’s approach is a culture-free, rapid pan-pathogen identification system that can detect bacteria, fungal, viral and parasitic pathogens directly from a patient’s sample. The whole process can be done in fewer than 60 minutes, making it the first rapid, comprehensive, direct-from-patient sample, microbial identification system. When implemented, it will provide the needed diagnostic guidance not only for the treatment of COVID-19 complications, but also infections in general.